Monivent (MONI) Q1 2026 earnings summary

Executive summary

• Organization strengthened with two new technical team members to support regulatory and product development focus.

• Main focus remains on securing regulatory approvals for European (MDR) and US (FDA) markets.

• Distribution strategy shifting to global partners, allowing internal focus on product and manufacturing.

• Financing process ongoing, with positive board outlook despite delays.

Financial highlights

• Net sales for Q1 2026 were 279 KSEK, down from 668 KSEK in Q1 2025.

• EBIT for Q1 2026 was -2,539 KSEK, compared to -2,173 KSEK in Q1 2025.

• Cash and cash equivalents at period end were 986 KSEK, down from 4,400 KSEK a year earlier.

• Equity ratio at period end was 0%, compared to 61% in Q1 2025.

• Earnings per share for Q1 2026 was -0.03 SEK, compared to -0.04 SEK in Q1 2025.

Outlook and guidance

• Board and management are in active discussions with potential investors to secure long-term financing.

• Regulatory approval processes for both Europe and the US are progressing, with MDR feedback awaited and FDA submission planned in coming months.

• Commercial strategy aims for long-term profitability through global distribution partnerships.